IP Library Granted Patent US 12,357,569
Granted Patent B2
US 12,357,569 · App. 17/901,360 · Granted Jul 15, 2025

Infusing drug solution directly into brain fluid

Inventors: Daniel J. Abrams (Aurora, CO); Michael S. Canney (Denver, CO)
Assignee: Biogen MA Inc.
A61K9/0085A61K9/08A61K45/06A61M25/0043A61P25/08A61M2025/0056A61M2025/0175A61M39/0208
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,569
App. No.
17/901,360
Granted
Jul 15, 2025
Kind
B2
Abstract

An intraventricular access device for infusion of drugs and aspiration of cerebrospinal fluid (CSF). The device includes a container configured to couple to an aspiration lumen through which CSF may be aspirated or through which drugs may be injected. The container is further configured to couple to an infusion lumen and to a drug pump via a catheter. The container thus forms a pathway connectable to the catheter through which a drug from the drug pump may be infused to flow through the infusion lumen into the CSF. The container includes a volume that is accessible by an aspiration needle, for example through a material that reseals upon extraction of the needle. Moreover, the container is configured to prevent cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen.

Claims (26)

1. An intraventricular access device comprising:

a container configured to couple to an aspiration lumen through which cerebrospinal fluid (CSF) may be aspirated or through which drugs may be injected,

wherein the container is further configured to couple to a catheter configured to couple to a drug pump,

the container is further configured to couple to an infusion lumen,

wherein the container comprises:

an infusion pathway connectable to the catheter through which a drug from the drug pump may be infused to flow through the infusion lumen into the CSF;

a portion formed from material that is penetrable by a needle and which substantially reseals upon extraction of the needle, wherein the container is configured such that penetration of the needle through the portion places the needle in fluid communication with a volume within the container that is in fluid communication with the aspiration lumen; and

a barrier configured to inhibit penetration of the needle into the infusion pathway when the needle is in fluid communication with the volume within the container that is in fluid communication with the aspiration lumen,

wherein the container includes a marker that is a distinct structure from the barrier and configured to directly indicate a position of the barrier during and/or after implantation of the container, and

wherein the container is configured to prevent cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen.

2. The intraventricular access device of claim 1 , further comprising a first side and an opposing second side, wherein the portion formed from the material that is penetrable by the needle is located on the first side of the intraventricular access device, and wherein the intraventricular access device is configured to connect to the aspiration lumen and the infusion lumen on the second side of the device.

3. The intraventricular access device according to claim 1 , wherein the intraventricular access device is configured to connect to the catheter configured to couple to the drug pump on a side of the intraventricular access device.

4. The intraventricular access device of claim 1 , wherein the barrier is composed of a metal or hard plastic.

5. A system comprising:

the intraventricular access device of claim 1 ;

the infusion lumen couplable to the intraventricular access device; and

the aspiration lumen couplable to the intraventricular access device.

6. The system of claim 5 , wherein the infusion lumen is configured to extend from the intraventricular access device, when implanted, to a cerebral ventricle, and wherein the aspiration lumen is configured to extend from the intraventricular access device, when implanted, to the cerebral ventricle.

7. The system of claim 5 , wherein the infusion lumen and the aspiration lumen have different lengths.

8. A system comprising:

the intraventricular access device of claim 1 ; and

the drug pump operably couplable to the intraventricular access device.

9. The system of claim 8 , further comprising the catheter configured to couple the drug pump to the intraventricular access device.

10. The system of claim 8 , further comprising the infusion lumen couplable to the intraventricular access device and the aspiration lumen couplable to the intraventricular access device.

11. The system of claim 10 , wherein the infusion lumen is configured to extend from the intraventricular access device, when implanted, to a cerebral ventricle, and wherein the aspiration lumen is configured to extend from the intraventricular access device, when implanted, to the cerebral ventricle.

12. The system of claim 10 , wherein the infusion lumen and the aspiration lumen have different lengths.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2024
From: CEREBRAL THERAPEUTICS, INC.
To: BIOGEN MA INC.
Reel/Frame 069104/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: ABRAMS, DANIEL J.; CANNEY, MICHAEL S.
To: CEREBRAL THERAPEUTICS, LLC.
Reel/Frame 060973/0670 →
CHANGE OF NAME Recorded Sep 2, 2022
From: CEREBRAL THERAPEUTICS, LLC
To: CEREBRAL THERAPEUTICS, INC.
Reel/Frame 061371/0585 →
Continuity (4)
Continuation 16252113 · Jan 18, 2019
Continuation In Part 15663095 · Jul 28, 2017
Provisional Application 62367713 · Jul 28, 2016
Related Publication 20220409530A1 · Dec 29, 2022
References Cited (55)
US 3640269A · Delgado · 1972 [cited by examiner]
US 4464168A · Redmond et al. · 1984 [cited by applicant]
US 4723556A · Sussman · 1988 [cited by applicant]
US 4767410A · Moden · 1988 [cited by examiner]
US 4904241A · Bark · 1990 [cited by applicant]
US 5522807A · Luther · 1996 [cited by applicant]
US 5720720A · Laske et al. · 1998 [cited by applicant]
US 5810789A · Powers et al. · 1998 [cited by applicant]
US 6013051A · Nelson · 2000 [cited by applicant]
US 6293922B1 · Haase · 2001 [cited by applicant]
US 7670327B2 · Kucharczyk et al. · 2010 [cited by applicant]
US 8277425B2 · Girard et al. · 2012 [cited by applicant]
US 8808234B2 · Vogelbaum et al. · 2014 [cited by applicant]
US 8979822B2 · Vogelbaum et al. · 2015 [cited by applicant]
US 20030135148A1 · Dextradeur et al. · 2003 [cited by applicant]
US 20040002677A1 · Gentsler · 2004 [cited by applicant]
US 20040073196A1 · Adams et al. · 2004 [cited by applicant]
US 20040171983A1 · Sparks et al. · 2004 [cited by applicant]
US 20050004219A1 · Hildebrand · 2005 [cited by applicant]
US 20050038371A1 · Reich et al. · 2005 [cited by applicant]
US 20050070458A1 · John · 2005 [cited by examiner]
US 20050137578A1 · Heruth et al. · 2005 [cited by applicant]
US 20050209332A1 · Kuppuswamy · 2005 [cited by applicant]
US 20060160889A1 · Hildebran et al. · 2006 [cited by applicant]
US 20070083063A1 · Nelson et al. · 2007 [cited by applicant]
US 20080039774A1 · Zawacki · 2008 [cited by examiner]
US 20080262374A1 · Gerber · 2008 [cited by applicant]
US 20090131850A1 · Geiger · 2009 [cited by applicant]
US 20090131857A1 · Geiger · 2009 [cited by examiner]
US 20100158869A1 · Kaemmerer · 2010 [cited by applicant]
US 20100286585A1 · DiMauro · 2010 [cited by examiner]
US 20100305492A1 · Lad et al. · 2010 [cited by applicant]
US 20110033463A1 · Thakker · 2011 [cited by applicant]
US 20110092921A1 · Beling · 2011 [cited by applicant]
US 20110172633A1 · Ali · 2011 [cited by applicant]
US 20110275930A1 · Jho · 2011 [cited by examiner]
US 20120087869A1 · Thakker · 2012 [cited by applicant]
US 20120310140A1 · Kramer · 2012 [cited by applicant]
US 20130253266A1 · Dextradeur · 2013 [cited by applicant]
US 20140257168A1 · Gill · 2014 [cited by applicant]
US 20150238685A1 · Elias et al. · 2015 [cited by applicant]
US 20150297874A1 · East et al. · 2015 [cited by applicant]
US 20160122282A1 · Kandula · 2016 [cited by applicant]
US 20160374901A9 · Rodriguez et al. · 2016 [cited by applicant]
WO 9427587 · 1994 [cited by applicant]
WO 2008115919 · 2008 [cited by applicant]
WO 2009014762 · 2009 [cited by applicant]
WO 2009151741 · 2009 [cited by applicant]
WO 2018023041A1 · 2018 [cited by applicant]
WO 2019084038A1 · 2019 [cited by applicant]
Abrams “Feasibility of Delivery of Anti-Epilepsy Medications into the Cerebrospinal Fluid (10802)” Neuromodulation, vol. 19, No. 3, p. e107, Dec. 10, 2015. [cited by applicant]
Barcia et al. “Intraventricular and Intracerebral Delivery of Anti-epileptic Drugs in the Kindling Model”, vol. 6, No. 2, pp. 337-343, Apr. 1, 2009. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/068592 dated Apr. 24, 2020, 12 pages. [cited by applicant]
Serralta et al. “Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model”, vol. 70, No. 1, pp. 15-26 Jul. 1, 2006. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/044452 mailed Nov. 2, 2017. Examiner: Schulze, Cornelia. Pages: 15. [cited by applicant]